We believe that this new information could establish the ground work for developing novel therapeutic agents that would effectively target HA/CD44-activated signaling events and specific downstream target molecules/functions in tumor cells-thus providing important new cancer therapies. The gene discussed is CD44; the disease is neoplasm.